Alejandro González‐Mora
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alejandro González‐Mora has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Federico Ruiz‐Ruiz
Escuela de Ingeniería y Ciencias Tecnologico de Monterrey Monterrey Mexico
3 shared publications- Jorge Benavides
Tecnologico de Monterrey, School of Engineering and Science, Ave. Eugenio Garza Sada Sur 2501 C.P. 64849, Monterrey, N.L., Mexico
3 shared publications - Marco Rito-Palomares
Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud Monterrey Mexico
3 shared publications - Hafiz Muhammad Nasir Iqbal
Tecnologico de Monterrey, School of Engineering and Sciences, Monterrey, Mexico
1 shared publication - Jesús Hernández-Pérez
Tecnológico de Monterrey, Escuela de Ingeniería y Ciencias, Monterrey, Mexico
1 shared publication Jorge Benavides
Centro de Biotecnología‐FEMSA, Tecnológico de Monterrey Campus Monterrey. Monterrey NL México
1 shared publication
Latest Publications
- Open Access
Bacteriophage-Based Vaccines: A Potent Approach for Antigen Delivery
Vaccines are considered one of the most important bioproducts in medicine. Since the development of the smallpox vaccine in 1796, several types of vaccines for many diseases have been created. However, some vaccines have shown limitations as high cost and low immune responses. In that regard, bacteriophages have been proposed as an attractive alternative for the development of more cost-effective vaccines. Phage-displayed vaccines consists in the expression of antigens on the phage surface. This approach takes advantage of inherent properties of these particles such as their adjuvant capacity, economic production and high stability, among others. To date, three types of phage-based vaccines have been developed: phage-displayed, phage DNA and hybrid phage-DNA vaccines. Typically, phage display technology has been used for the identification of new and protective epitopes, mimotopes and antigens. In this context, phage particles represent a versatile, effective and promising alternative for the development of more effective vaccine delivery systems which should be highly exploited in the future. This review describes current advances in the development of bacteriophage-based vaccines, with special attention to vaccine delivery strategies. Moreover, the immunological aspects of phage-based vaccines, as well as the applications of phage display for vaccine development, are explored. Finally, important challenges and the future of phage-bases vaccines are discussed.
Open AccessBacteriophage-Based Vaccines: A Potent Approach for Antigen Delivery
Vaccines are considered one of the most important bioproducts in medicine. Since the development of the smallpox vaccine in 1796, several types of vaccines for many diseases have been created. However, some vaccines have shown limitations as high cost and low immune responses. In that regard, bacteriophages have been proposed as an attractive alternative for the development of more cost-effective vaccines. Phage-displayed vaccines consists in the expression of antigens on the phage surface. This approach takes advantage of inherent properties of these particles such as their adjuvant capacity, economic production and high stability, among others. To date, three types of phage-based vaccines have been developed: phage-displayed, phage DNA and hybrid phage-DNA vaccines. Typically, phage display technology has been used for the identification of new and protective epitopes, mimotopes and antigens. In this context, phage particles represent a versatile, effective and promising alternative for the development of more effective vaccine delivery systems which should be highly exploited in the future. This review describes current advances in the development of bacteriophage-based vaccines, with special attention to vaccine delivery strategies. Moreover, the immunological aspects of phage-based vaccines, as well as the applications of phage display for vaccine development, are explored. Finally, important challenges and the future of phage-bases vaccines are discussed.
- 6 July 2020
- Published by Wiley in Journal of Chemical Technology & Biotechnology
- Vol. 95 (11) , 2822-2833
Economic evaluation of M13 bacteriophage production at large‐Scale for therapeutic applications using aqueous Two‐Phase systems
BACKGROUND: Bacteriophages are bionanoparticles with several applications in different biotechnology‐based products. Among them, vaccines have the potential to treat antibiotic‐resistant bacteria and parasitic infections. Traditional methods for their recovery and purification rely on precipitation with polyethylene glycol (PEG) and NaCl. However, the applicability of such an approach is limited, due to large‐scale technical constrains. Recently, our research group developed a bacteriophage M13 recovery and purification strategy using Aqueous Two‐Phase Systems (ATPS), simplifying the methodology and, potentially, reducing costs. This work aims to develop an economic contrast between ATPS and the traditional PEG precipitation method at different operation scales (10 to 1000 L bioreactor volume) to determine the applicability of the ATPS methodology at large scale. For this, the effect of ATPS volume ratio (VR), sample loading, and materials discount over production cost were analyzed.RESULTS: Results indicate that as the discount on material costs increases, ATPS becomes a more affordable unit operation, from a bioreactor scale of 10 L at 0% discount to 410 L at 90% discount (US$ 52.2 to $1.72 per gram, respectively). Material cost contribution is a parameter that needs attention when working with ATPS, as it is the core for the system construction. Methods for reducing their contribution are highly relevant and should be further investigated.CONCLUSION: Employment of economic analyses help to discover critical parameters for a bioprocess, such as material costs for ATPS. This economic analysis work serves as a platform for new strategies for the recovery of bacteriophage and bacteriophage‐like particles using ATPS‐based technologies. © 2020 Society of Chemical Industry (SCI)
- 6 July 2020
- Published by Wiley in Journal of Chemical Technology & Biotechnology
- Vol. 95 (11) , 2822-2833
Economic evaluation of M13 bacteriophage production at large‐Scale for therapeutic applications using aqueous Two‐Phase systems
BACKGROUND: Bacteriophages are bionanoparticles with several applications in different biotechnology‐based products. Among them, vaccines have the potential to treat antibiotic‐resistant bacteria and parasitic infections. Traditional methods for their recovery and purification rely on precipitation with polyethylene glycol (PEG) and NaCl. However, the applicability of such an approach is limited, due to large‐scale technical constrains. Recently, our research group developed a bacteriophage M13 recovery and purification strategy using Aqueous Two‐Phase Systems (ATPS), simplifying the methodology and, potentially, reducing costs. This work aims to develop an economic contrast between ATPS and the traditional PEG precipitation method at different operation scales (10 to 1000 L bioreactor volume) to determine the applicability of the ATPS methodology at large scale. For this, the effect of ATPS volume ratio (VR), sample loading, and materials discount over production cost were analyzed.RESULTS: Results indicate that as the discount on material costs increases, ATPS becomes a more affordable unit operation, from a bioreactor scale of 10 L at 0% discount to 410 L at 90% discount (US$ 52.2 to $1.72 per gram, respectively). Material cost contribution is a parameter that needs attention when working with ATPS, as it is the core for the system construction. Methods for reducing their contribution are highly relevant and should be further investigated.CONCLUSION: Employment of economic analyses help to discover critical parameters for a bioprocess, such as material costs for ATPS. This economic analysis work serves as a platform for new strategies for the recovery of bacteriophage and bacteriophage‐like particles using ATPS‐based technologies. © 2020 Society of Chemical Industry (SCI)
- 8 June 2018
- Published by Wiley in Biotechnology Progress
- Vol. 34 (5) , 1177-1184
Improved recovery of bacteriophage M13 using an ATPS‐based bioprocess
Aqueous two‐phase systems (ATPS) have been widely exploited for the recovery and partial purification of biological compounds. Recently our research group characterized the primary recovery and partial purification of bacteriophage M13 using polymer‐salt and ionic liquid‐salt ATPS. From such study, it was concluded that PEG 400‐potassium phosphate ATPS with a volume ratio ( V R ) of 1 and 25% w/w TLL were the best suitable for the primary recovery of bacteriophage M13 from a crude extract, achieving a recovery yield of 83.3%. Although such system parameters were proven to be adequate for the recovery of the product of interest, it was concluded that further optimization was desirable and attainable by studying the effect of additional system parameters such as V R , concentration of neutral salt (M) and sample load (% w/w). This research work presents an optimization of a previously reported process for the recovery of bacteriophage M13 directly from a crude extract using ATPS. The increase in V R and sample load showed a positive effect in the recovery of M13 indicating an improved performance of the proposed ATPS. According to the results presented here, a system composed of PEG 400 17.2% (w/w), potassium phosphate 15.5% (w/w) and a sample load of 30% (w/w) allowed the recovery of M13 directly from a crude extract with a top phase recovery of 80.1%, representing an increase of 4.8 times in the final concentration and a reduction of 2.65 times in the processing costs. © 2018 American Institute of Chemical Engineers Biotechnol. Prog. , 2018 © 2018 American Institute of Chemical Engineers Biotechnol. Prog. , 34:1177–1184, 2018
- 8 June 2018
- Published by Wiley in Biotechnology Progress
- Vol. 34 (5) , 1177-1184
Improved recovery of bacteriophage M13 using an ATPS‐based bioprocess
Aqueous two‐phase systems (ATPS) have been widely exploited for the recovery and partial purification of biological compounds. Recently our research group characterized the primary recovery and partial purification of bacteriophage M13 using polymer‐salt and ionic liquid‐salt ATPS. From such study, it was concluded that PEG 400‐potassium phosphate ATPS with a volume ratio ( V R ) of 1 and 25% w/w TLL were the best suitable for the primary recovery of bacteriophage M13 from a crude extract, achieving a recovery yield of 83.3%. Although such system parameters were proven to be adequate for the recovery of the product of interest, it was concluded that further optimization was desirable and attainable by studying the effect of additional system parameters such as V R , concentration of neutral salt (M) and sample load (% w/w). This research work presents an optimization of a previously reported process for the recovery of bacteriophage M13 directly from a crude extract using ATPS. The increase in V R and sample load showed a positive effect in the recovery of M13 indicating an improved performance of the proposed ATPS. According to the results presented here, a system composed of PEG 400 17.2% (w/w), potassium phosphate 15.5% (w/w) and a sample load of 30% (w/w) allowed the recovery of M13 directly from a crude extract with a top phase recovery of 80.1%, representing an increase of 4.8 times in the final concentration and a reduction of 2.65 times in the processing costs. © 2018 American Institute of Chemical Engineers Biotechnol. Prog. , 2018 © 2018 American Institute of Chemical Engineers Biotechnol. Prog. , 34:1177–1184, 2018
- 4 August 2017
- Published by Wiley in Journal of Chemical Technology & Biotechnology
- Vol. 92 (11) , 2808-2816
Recovery and primary purification of bacteriophage M13 using aqueous two‐phase systems
BACKGROUND: Bacteriophage M13 is an Escherichia coli‐specific non‐lytic filamentous virus commonly used in applications ranging from antibody screening and nanomaterial construction to drug delivery, among others. In this tenor, alternative methods for the fractionation, recovery and partial purification of phage particles are desired. In this work, the use of aqueous two‐phase systems (ATPS) was evaluated as an alternative method for the recovery of phage particles.RESULTS: The partition behavior of M13 in PEG–salt and ionic liquid (IL)–salt ATPS was characterized using a pre‐purified feedstock. In PEG‐salt ATPS, M13 was preferentially partitioned to the interface. In IL ATPS, however, M13 showed a high‐top phase preference with recovery yields above 65%. Selected systems were tested for the extraction of M13 from a crude fermentation broth. From crude broth, a PEG 400‐potassium phosphate system with volume ratio (VR) of 1 and 25% w/w tie line length (TLL) gave the best M13 top phase recovery (83%) and purification fold (18.2) in terms of total protein concentration.CONCLUSIONS: The results presented here demonstrate the practical application of ATPS as an efficient process for the primary recovery and partial purification of M13 and represent the first study of the extraction of viral particles directly from a crude broth as well as the use of IL‐Salt ATPS. © 2017 Society of Chemical Industry
- 4 August 2017
- Published by Wiley in Journal of Chemical Technology & Biotechnology
- Vol. 92 (11) , 2808-2816
Recovery and primary purification of bacteriophage M13 using aqueous two‐phase systems
BACKGROUND: Bacteriophage M13 is an Escherichia coli‐specific non‐lytic filamentous virus commonly used in applications ranging from antibody screening and nanomaterial construction to drug delivery, among others. In this tenor, alternative methods for the fractionation, recovery and partial purification of phage particles are desired. In this work, the use of aqueous two‐phase systems (ATPS) was evaluated as an alternative method for the recovery of phage particles.RESULTS: The partition behavior of M13 in PEG–salt and ionic liquid (IL)–salt ATPS was characterized using a pre‐purified feedstock. In PEG‐salt ATPS, M13 was preferentially partitioned to the interface. In IL ATPS, however, M13 showed a high‐top phase preference with recovery yields above 65%. Selected systems were tested for the extraction of M13 from a crude fermentation broth. From crude broth, a PEG 400‐potassium phosphate system with volume ratio (VR) of 1 and 25% w/w tie line length (TLL) gave the best M13 top phase recovery (83%) and purification fold (18.2) in terms of total protein concentration.CONCLUSIONS: The results presented here demonstrate the practical application of ATPS as an efficient process for the primary recovery and partial purification of M13 and represent the first study of the extraction of viral particles directly from a crude broth as well as the use of IL‐Salt ATPS. © 2017 Society of Chemical Industry